New drug aims to lighten heavy periods for bleeding disorder patients
NCT ID NCT07575308
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This study tests an investigational drug called ALN-6400 in 24 women and teens with von Willebrand disease who have heavy menstrual bleeding. The goal is to see if the drug is safe and can reduce bleeding. Participants will receive multiple doses and be monitored for side effects and changes in bleeding patterns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAVY MENSTRUAL BLEEDING (HMB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Trial Site
RECRUITINGLos Angeles, California, 90027, United States
-
Clinical Trial Site
RECRUITINGOrange, California, 92868, United States
-
Clinical Trial Site
RECRUITINGMiami, Florida, 33024, United States
-
Clinical Trial Site
RECRUITINGLexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New shot aims to tame bleeding disorder in small trial
- New algorithm aims to stop dangerous bleeding in VWD patients
- Family history questions may improve bleeding disorder detection in kids
- UK doctors look back at real-world use of new VWD drug
- New study tracks bleeding drug in kids
- New study aims to uncover hidden bleeding disorder in egyptian kids